Early CAR T-cell therapy in relapsed/refractory large B-cell lymphoma is associated with lower hematotoxicity burden. Vanja Zeremski, Enver Aydilek, Akhil Behringer, Franziska Brunner, Tobias Ronny Haage, Mathias Haenel, Igor Age Kos, William Hermann Krueger, Georg Lenz, Vadim Lesan, Jessica Schneider, Christian R Schultze-Florey, Evgenii Shumilov, Thomas Weber, Gerald Georg Wulf, Vladan Vucinic, Dimitrios Mougiakakos Blood Advances 2025 December 18

https://read.qxmd.com/read/41411524/early-car-t-cell-therapy-in-relapsed-refractory-large-b-cell-lymphoma-is-associated-with-lower-hematotoxicity-burden?uac=148436CN&ecd=wnl_readmost_251226&sso=true&redirected=slug Early CAR T-cell therapy in relapsed/refractory large B-cell lymphoma is associated with lower hematotoxicity burden. Dec 18, 2025: Blood Advances